Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 3/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22502002 | 0.95 | HSP90AA1 (0.35) | HSP90AA1HSP90AB1NQO2LCKACACB | |
| SCHEMBL22502015 | 0.92 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1NQO2LCKACACB | |
| SCHEMBL22501987 | 0.86 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1NQO2LCKACACB | |
| SCHEMBL31546947 | 0.86 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1NQO2LCKACACB | |
| SCHEMBL30588742 | 0.84 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1NQO2ACACBACACA | |
| SCHEMBL26129010 | 0.84 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1NQO2ACACBACACA | |
| SCHEMBL24323283 | 0.83 | LMNA (0.37) | HSP90AA1HSP90AB1LCK | |
| SCHEMBL29600537 | 0.83 | LMNA (0.37) | HSP90AA1HSP90AB1LCK | |
| SCHEMBL25346452 | 0.81 | HSP90AA1 (0.33) | HSP90AA1HSP90AB1 | |
| SCHEMBL24326460 | 0.81 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1ACACBACACAPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421251-B2 | Cystic fibrosis transmembrane conductance regulator modulating agents | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-23 | — | — | US | disclosed |
| CN-113905785-B | Cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4335498-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | Vertex Pharmaceuticals Incorporated (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3946595-B1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMA (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220372047-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-11-24 | — | — | US | disclosed |
| EP-3946595-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | Vertex Pharmaceuticals Incorporated (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113905785-A | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2022-01-07 | — | — | CN | disclosed |
| WO-2020206080-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372047-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | CFTR, SCNN1G, CLCN2 | HSP90AA1 1899/4885HSP90AB1 1426/4885NQO2 351/4885 |
| US-12421251-B2 | Cystic fibrosis transmembrane conductance regulator modulating agents | CFTR, SCNN1G, CLCN2 | HSP90AA1 1899/4885HSP90AB1 1426/4885NQO2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.